CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

15 Nov 2024 09:00:00 By Nasdaq GlobeNewswire

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

14 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

12 Nov 2024 16:07:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

16 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2024 16:40:28 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

08 Oct 2024 23:55:11 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

08 Oct 2024 16:01:51 By Nasdaq GlobeNewswire

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

26 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2024 16:40:25 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 16:05:01 By Nasdaq GlobeNewswire

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

08 Aug 2024 08:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

18 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jul 2024 19:29:44 By Nasdaq GlobeNewswire

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

18 Jun 2024 16:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2024 18:35:30 By Nasdaq GlobeNewswire

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

03 Jun 2024 12:00:00 By Nasdaq GlobeNewswire